ADAP News and Press, Adaptimmune Therapeutics plc From 04/11/23

- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy - - Adaptimmune and GSK will work collaboratively to ensure continuity for patients in ongoing clinical trials for lete-cel and next generation TCR T-cells targeting NY-ESO - -Adaptimmune will receive £30 ...

NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Global Infrastructure, Inc....

2023-03-26 07:12:58 ET Summary ADAP is down after merging with TCRR, while TCRR is up. The merger dilutes ADAP, but in return, it gets one year of additional cash and the TCRR pipeline for free. The merger looks like a smart deal for ADAP. For further det...

2023-03-06 15:40:06 ET Adaptimmune Therapeutics plc (ADAP) Q4 2022 Earnings Conference Call March 06, 2023, 08:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Garry Menzel - President and Chief Execut...

2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...

2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...

2023-03-06 08:17:23 ET Aclaris Therapeutics ( ACRS ) -38% after preliminary topline data from 12-week Phase 2a study did not meet primary or secondary efficacy endpoints in hidradenitis suppurativa . Esperion Therapeutics ( ESPR ) -27% amid Nexletol data ...

2023-03-06 07:27:05 ET Shares of Adaptimmune Therapeutics ( NASDAQ: ADAP ) are down 26% premarket despite Q4 earnings beat after the company announced a strategic agreement with TCR² Therapeutics . Both the companies will combine in an all-stock transactio...

2023-03-06 06:44:44 ET Adaptimmune press release ( NASDAQ: ADAP ): Q4 GAAP EPS of -$0.03 beats by $0.20 . Revenue of $11.03M (+687.9% Y/Y) beats by $5.95M . As of December 31, 2022, Adaptimmune had cash and cash equivalents of $108.0 million and Total Liquidi...

BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed engineered TCR T-cell therapy for a solid tumor 52% (13/25) response rate in ovarian, bladder and head & neck cancers in the Phase 1 SURPASS trial with next-generati...